China Pharma Holdings (CPHI) Receivables - Net (2016 - 2025)
China Pharma Holdings (CPHI) has disclosed Receivables - Net for 16 consecutive years, with $294514.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Receivables - Net fell 97.94% year-over-year to $294514.0, compared with a TTM value of $294514.0 through Sep 2025, down 97.94%, and an annual FY2024 reading of $13.8 million, up 2639.49% over the prior year.
- Receivables - Net was $294514.0 for Q3 2025 at China Pharma Holdings, down from $13.9 million in the prior quarter.
- Across five years, Receivables - Net topped out at $14.3 million in Q4 2023 and bottomed at $29564.0 in Q4 2021.
- Average Receivables - Net over 5 years is $4.7 million, with a median of $444271.0 recorded in 2021.
- The sharpest move saw Receivables - Net surged 4972.2% in 2024, then crashed 97.94% in 2025.
- Year by year, Receivables - Net stood at $29564.0 in 2021, then surged by 1325.83% to $421531.0 in 2022, then skyrocketed by 3290.15% to $14.3 million in 2023, then decreased by 3.3% to $13.8 million in 2024, then crashed by 97.87% to $294514.0 in 2025.
- Business Quant data shows Receivables - Net for CPHI at $294514.0 in Q3 2025, $13.9 million in Q2 2025, and $328901.0 in Q1 2025.